This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery

This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery ipopba / iStock via Getty Images Investing in biopharmaceutical stocks comes with more risks than some other types of stocks. Just one unsuccessful clinical trial or a lack of funding can doom biotech startups. But the rewards can be great when investors are on to a winner. Take Novavax Inc. (NASDAQ: NVAX) for example, one of the winners in the race for a COVID-19 vaccine. The Maryland-based vaccine maker was founded in 1987. Its share ...